Literature DB >> 27663401

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.

Satoshi Anai1, Masafumi Takeshita2, Nobuhisa Ando2, Yuuki Ikematsu2, Shohei Mishima2, Koichi Ishida2, Kouji Inoue2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27663401     DOI： 10.1016/j.jtho.2016.07.008

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion.

Authors:  Cristina Aguado; Maria-de-Los-Llanos Gil; Zaira Yeste; Ana Giménez-Capitán; Cristina Teixidó; Niki Karachaliou; Santiago Viteri; Rafael Rosell; Miguel A Molina-Vila
Journal:  Onco Targets Ther       Date:  2018-03-01       Impact factor: 4.147

Review 2.  Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.

Authors:  Ryohei Katayama
Journal:  Cancer Sci       Date:  2018-02-15       Impact factor: 6.716
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.